Skip to main content


Figure 1 | EJNMMI Research

Figure 1

From: Evaluation of the specificity of [18F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [18F]FDG and impact of rituximab therapy

Figure 1

Volumetric assessment with [18F]fludarabine PET/CT and illustration of a delineation of MAVT. (a) Tumour growth in rituximab-treated (n = 5) and vehicle-treated mice (n = 5) - RM two-way ANOVA, *** p < 0.001. Error bars: ± standard error of the mean (SEM). (b) Contouring of metabolically active part of tumour (MAVT) based on segmentation with background (muscle) as threshold. The volume of non-avid tissues was assessed by subtracting the MAVT from the total tumour volume.

Back to article page